American Bioscience v. Thompson, No. 00-5350

• Court: United States Courts of Appeals. United States Court of Appeals (District of Columbia)
• Writing for the Court: Randolph
• Citation: 243 F.3d 579
• Parties: (D.C. Cir. 2001) American Bioscience, Inc., Appellant v. Tommy G. Thompson, Secretary of Health and Human Services, et al., Appellees
• Docket Number: No. 00-5350
• Decision Date: 30 March 2001

Page 579

243 F.3d 579 (D.C. Cir. 2001) American Bioscience, Inc., Appellant
v.
Tommy G. Thompson, Secretary of Health and Human Services, et al., Appellees No. 00-5350 United States Court of Appeals FOR THE DISTRICT OF COLUMBIA CIRCUIT Argued January 18, 2001
Decided March 30, 2001

Appeal from the United States District Court for the District of Columbia (00cv02247)

Joseph F. Coyne, Jr. argued the cause for appellant. With him on the briefs were Carlton A. Varner, Robert F. Green, Arthur Y. Tsien, David F. Weeda and Jacqueline H. Eagle. David L. Durkin entered an appearance.

Howard S. Scher, Attorney, U.S. Department of Justice, argued the cause for federal appellees. with him on the brief were David W. Ogden, Assistant Attorney General, Douglas N. Letter, Attorney, Wilma A. Lewis, U.S. Attorney, and Annamarie Kempic, Counsel, Food and Drug Administration.

Philip A. Sechler argued the cause for appellees Baker Norton Pharmaceuticals, Inc. and Zenith Goldline Pharmaceuticals, Inc. With him on the brief was Richard M. Cooper.

Before: Edwards, Chief Judge, Sentelle and Randolph, Circuit Judges.

Opinion for the Court filed by Circuit Judge Randolph.

Randolph, Circuit Judge:

This appeal from the district court's judgment denying a preliminary injunction against the Food and Drug Administration requires us to consider once again the Supreme Court's opinion in Citizens to

Page 580

Preserve Overton Park v. Volpe, 401 U.S. 402 (1971). Although the procedural background of the appeal is complex, our reasons for vacating and remanding are simple: the administrative record was never filed in court and we cannot tell on what basis the Food and Drug Administration took the agency action the plaintiff seeks to enjoin.

The statutory framework is as follows. A company wishing to market a drug must seek FDA approval usually by completing a "New Drug Application" (NDA) containing data from tests showing the drug's safety and effectiveness. See Mova Pharmaceutical Corp. v. Shalala, 140 F.3d 1060, 1063 (D.C. Cir. 1998). The Hatch-Waxman Amendments to the Food, Drug and Cosmetic Act in 1984 made it easier for drug manufacturers to obtain approval of generic drugs. See Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified in scattered sections of 21, 35 & 42 U.S.C.). Under these amendments, a generic drug producer need not undertake the complicated and timeconsuming testing process associated with an NDA and can instead file an "Abbreviated New Drug Application" (ANDA), relying on the NDA filed by the original manufacturer. See 21 U.S.C. § 355(j); Mova Pharmaceutical Corp., 140 F.3d at 1063.

While making it easier to bring generic drugs to market, Congress also wanted to protect patent holders whose rights might be infringed by the generic drugs. The law, therefore, requires that NDAs contain a list of any patents "which claim[ ] the drug ... or which claim[ ] a method of using such drug and with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner engaged in the manufacture, use, or sale of the drug." 21 U.S.C. § 355(b)(1). If new patents claiming the drug or a method of using the drug are filed after the drug has been approved, the approved applicant must inform the Food and Drug Administration within 30 days. See 21 U.S.C. § 355(c)(2). The FDA keeps all of this information in a publication officially titled Approved Drug Products with Therapeutic Equivalence, commonly called the Orange Book. See 21 U.S.C. § 355(j)(7)(A).

The statute also includes patent protections when an Abbreviated New Drug Application is filed. For "each patent which claims" the drug the applicant would like to distribute in a generic version, the applicant must certify (1) that no patent has been filed with the FDA; or (2) that the patent has expired; or (3) that the patent has not expired, but will expire on a particular date; or (4) that the patent is either invalid or the generic drug will not infringe it. See 21 U.S.C. § 355(j)(2)(A)(vii).

The fourth of these options, known as a Paragraph IV certification, is central to the case as the parties have framed it. When a generic drug applicant certifies that a patent is invalid or that its proposed generic drug will not infringe upon it, it must also certify that it will give notice to the patent holder that it has entered the Paragraph IV certification. See 21 U.S.C. § 355(j)(2)(B). If the patent holder has not filed a patent infringement action within 45 days of receiving this notice, the FDA may immediately approve the ANDA. See 21 U.S.C. § 355(j)(5)(B)(iii). However, if a patent infringement action is filed within 45 days, the FDA may not approve the ANDA for 30 months, or until the patent dispute has been resolved, whichever is sooner. See 21 U.S.C. § 355(j)(5)(B)(iii).

Bristol Meyers-Squibb has FDA approval to manufacture and distribute Taxol, an anti-cancer drug with the active ingredient paclitaxel. American Bioscience allegedly developed a new process that permits a patient to receive higher doses of Taxol with fewer side effects. American Bioscience received U.S. Patent Number 6,906,331 (the '331 patent) for this process on August 1, 2000. Bristol Meyers refused to inform the FDA of this new patent. See 21 U.S.C. § 355(c)(2). American

Page 581

Bioscience then sued Bristol Meyers in the Central District of California, asking the court to compel Bristol Meyers to submit the patent for listing in the FDA's Orange Book. On August 11, the court entered a temporary restraining order requiring Bristol Meyers to list the drug with the FDA...